Ms. Mucha brings 25 years of executive administration experience to the Artizan team. Most recently, she worked at Alexion Pharmaceutical in the Global Business Development and Strategy Department. Additionally, Ms. Mucha spent more than 20 years in financial services at various Fortune 500 companies where she managed complex events and helped onboard and staff growing businesses. She received her B.A. in Business Administration from American InterContinental University.

Mr. John brings his prior experience in the agricultural biotech industry to the Artizan team. Prior to joining the company, he worked as a microbiology research associate at Native Microbials, where he developed live microbial supplements for livestock and companion animals. As a member of the microbial discovery team at Bayer Crop Science, Mr. John helped develop microbial products intended to improve crop efficacy. He received his B.S. in Animal Biology from the University of California, Davis.

Prior to joining Artizan, Ms. Cooney-Walsh worked at Bristol-Myers Squibb for 13 years as a veterinary scientist where she performed lab animal research and discovered a passion for the animals that lead to many important scientific discoveries. She began her career working in a zoo and a small animal veterinary practice. She received her B.S. in Zoology from Washington State University and holds a certificate as a Laboratory Animal Technologist with the American Association for Laboratory Animal Science.

Ms. Chintha brings more than 10 years of industrial experience to Artizan in the fields of microbiome, virology, immunology, molecular biology and biochemistry including target validation through progressing lead candidates into clinical trials. Prior to joining Artizan, she worked as a Senior R&D Specialist in the Infectious Diseases department at Regeneron Pharmaceuticals. Ms. Chintha received her M.S. in Biological Sciences from University of Massachusetts and her B.S. in Biotechnology from Jawaharlal Nehru Technological University.

Mr. Robinson has nearly 30 years of pharmaceutical research experience. He joined Artizan after spending a decade working to develop oncology therapeutics at two New Haven-based biotechnology companies, Kolltan and Cybrexa. He began his career studying yeast replication at the UConn Health Center and transitioned to developing small molecule and biological therapeutics targeting HIV and hepatitis C virus at Bristol-Myers Squibb and osteoporosis and diabetes at Pfizer. Mr. Robinson received his B.S. in Microbiology from the University of Connecticut.

Ms. Ledoux has more than a decade of experience in lab management and operations in both academia and biotech, building safety programs, procurement systems and using technology to streamline laboratory operations. Prior to Artizan, she served as Laboratory Manager for Assembly Biosciences, supporting the cGMP microbiome CMC group with Phase 1 clinical supply development, manufacture and release. Ms. Ledoux is in the process of completing her Project Management Professional certification to support the therapeutic development programs as they mature. She received her B.S. in Biology from Massachusetts College of Liberal Arts.

Dr. Hoekstra has worked in pharmaceutical R&D as a medicinal chemist and intellectual property coordinator for more than 30 years. Prior to joining Artizan, he served as Senior Vice President of Medicinal Chemistry at Viamet Pharmaceuticals Inc., where he co-invented the Phase 3 antifungal oteseconazole and the Phase 2B anticancer agent seviteronel. Prior to working with Viamet, Dr. Hoekstra held the position of Associate Director in Discovery Medicinal Chemistry at GlaxoSmithKline where he coordinated the introduction of a group of nuclear receptor modulator programs into the portfolio. In the 1990s, he directed the discovery and lead optimization of several clinical new chemical entities such as the Phase 2B antithrombotic elarofiban in Johnson & Johnson’s Department of Drug Discovery. Dr. Hoekstra has co-authored over 100 publications, holds 75 issued U.S. patents and has presented several invited lectures. He received his B.S. in Chemistry from Hope College, Holland, MI and subsequently earned his Ph.D. in Organic Chemistry from Emory University, Atlanta, GA.

Dr. Schofield’s academic career focused on the molecular mechanisms that enable bacteria to propagate and thrive in the mammalian host. He completed his doctoral work in the laboratory of Christine Jacobs-Wagner, where he studied bacterial chromosome segregation by developing novel image analysis software. His post-doctoral work was done with Andrew Goodman at Yale University, where he utilized transcriptomics, metabolomics and epistasis analysis to elucidate how human gut bacteria adjust central carbon metabolism to the mammalian digestive tract.

Dr. Miller is the Chief Scientific Officer and is responsible for all facets of Artizan’s research and development organization and portfolio. Prior to joining Artizan in 2019, he was Chief Scientific Officer at Synlogic where he established the company’s research team and helped guide it to advance a novel, engineered, live microbial biotherapeutic platform from idea to first-in-human studies in under three years. Previously, Dr. Miller was the Vice President of Infection Biology at AstraZeneca where he was responsible for the early discovery portfolio and strategy, while also leading several external collaborations. Prior to AstraZeneca, Dr. Miller was the Chief Scientific Officer for Antibacterial Research at Pfizer, leading discovery teams that produced eight drug development candidates, provided critical research support for several successful marketed antibiotics including Zithromax and Zyvox and advanced a novel oxazolidinone (sutezolid) for tuberculosis into Phase 2 studies. A microbial geneticist by training, he began his professional career at the Warner-Lambert Company in Ann Arbor, Michigan, where he integrated cutting edge molecular-genetic approaches into a traditional antibacterial drug discovery program and established novel target discovery projects. His work there led to new insights into the mechanisms by which bacteria sense and respond to antibiotics and other environmental agents. Dr. Miller has served as a member of the Institute of Medicine’s Forum on Microbial Threats and also is a scientific advisor to the CARB-X antibacterial funding initiative as well as the Bill and Melinda Gates Foundation in the area of tuberculosis drug discovery. He received his Ph.D. in Microbiology and Immunology from the Albany Medical College and conducted post-doctoral studies in yeast genetics at the National Institutes of Health.

Prior to Artizan’s inception, Mr. Rosen spent 12 years in venture capital, most recently leading the program-related venture capital investment function for the Bill & Melinda Gates Foundation in Seattle. Mr. Rosen spent a decade with Intersouth Partners, where he worked his way from intern to Partner on the life sciences investment team. Prior to joining Intersouth, he spent 15 years in clinical, research and financial positions in the health care and biotechnology sectors. His research experience includes programs at the Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill (UNC), the National Cancer Institute, Duke University Medical Center and its Comprehensive Cancer Center. Mr. Rosen also managed clinical trials at a privately held contract research organization, which led to FDA-approved products. He spent several years as an equity research analyst at Brean Murray & Co., covering biopharmaceuticals, genomics, generics, drug delivery and medical device companies. Prior to his research and Wall Street functions, Mr. Rosen spent five years in Emergency Medical Services as a mountain search & rescue and ambulance medic. He currently serves on numerous boards and advisory committees, including the UNC’s Public Health Foundation Board (Emeritus, Chairman) and Dean’s Advisory Council for the Gillings School of Global Public Health at UNC, the Carolina Research Ventures Advisory Board and the Oversight Committee for the Duke-Coulter Translational Partners Program. Mr. Rosen holds a B.A. from Duke University and an M.B.A. from UNC’s Kenan-Flagler School of Business where he was a Carolina Venture Fellow and recipient of the Frank Hawkins Kenan Award for Excellence. He received his M.S.P.H. from the UNC School of Public Health, where his thesis focused on the relationship between technology transfer in biotechnology and venture capital investment. In 2010, he was awarded the Eisenhower Fellowship for which he designed and executed a program to evaluate the prospects for health care innovation in China and Southeast Asia.